Table 2.
Concentration of cyokines and chemokines in serum from patients treated with Zoledronate and interleukin (IL)-2.
| Months after treatment |
|||
|---|---|---|---|
| 0 | 3 | 9 | |
| IL-8 | 52·1 ± 113·5 | 25·9 ± 36·5* | 28·3 ± 49·9* |
| Eotaxin | 351·5 ± 327·5 | 736·7 ± 708·5* | 455·7 ± 217·3 |
| MIP-1α | 353·7 ± 257·1 | 777·3 ± 668·6* | 524·8 ± 284·9 |
| IP/10 | 670·0 ± 423·0 | 1314·8 ± 1159·1* | 904·8 ± 686·2l |
| MCP-1 | 157·9 ± 90·2 | 148·3 ± 133·5 | 94·1 ± 46·4 |
| IL12p40 | 368·5 ± 157·6 | 474·2 ± 481·1* | 587·0 ± 463·5* |
| IL12p70 | 22·0 ± 26·9 | 33·1 ± 35·3 | 11·5 ± 6·6* |
| IL-2 | 16·8 ± 15·1 | 12·6 ± 8·8 | 10·9 ± 7·7 |
| IL-4 | 5·4 ± 4·6 | 8·2 ± 4·7 | 4·7 ± 4·6 |
| IL-13 | 10·5 ± 10·3 | 16·9 ± 6·5 | 13·8 ± 8·8 |
| TNF-α | 19·2 ± 8·2 | 16·6 ± 7·6 | 18·3 ± 9·2* |
| GM-CSF | 14·6 ± 7·3 | 15·0 ± 8·9 | 18·8 ± 2·1* |
| IL-6 | 9·2 ± 14·0 | 14·9 ± 25·8 | 4·0 ± 3·8 |
| IFN-γ | 22·5 ± 12·2 | 47·9 ± 41·8* | 30·1 ± 14·5 |
| TRAIL | 42·7 ± 13·3 | 22·3 ± 14·4 | 17·2 ± 14·0 |
Data indicate the mean serum concentration (expressed in pg/ml) ± standard deviation (s.d.). GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN, interferon; IP, inositol phosphate; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; TRAIL, tumour necrosis factor (TNF)-related apoptosis-inducing ligand.